ATTAIN-MAINTAIN completes, testing a switch from injections to an oral GLP-1

A clinical trial called ATTAIN-MAINTAIN, registered on ClinicalTrials.gov under identifier NCT06584916, has finished enrolling and treating 376 participants who had plateaued while taking the highest dose they could tolerate of injectable tirzepatide or semaglutide in the earlier SURMOUNT-5 study ^[1]. Instead of staying on their injections, these participants were moved to either a once-daily oral pill called orforglipron or a placebo pill for 52 weeks ^[1].

Orforglipron is a GLP-1 medicine taken by mouth rather than by injection, unlike Ozempic, Wegovy, Mounjaro, or Zepbound, which all require weekly shots ^[1]. The trial's design lets researchers ask a specific question: when someone's weight loss has stalled on an injectable GLP-1 medicine at the highest dose they can handle, does switching to a different oral drug help them keep losing weight, or at least keep the weight off, over the following year ^[1]. The record available from ClinicalTrials.gov confirms the trial's structure, participant count, and one-year treatment period, but it does not include specific results such as how much weight participants lost or gained, or details on side effects ^[1].

Because the source document is the study's registration record rather than a results report, exact numbers on efficacy or safety from this switch have not yet been made public ^[1]. The registration confirms that the study tested a real-world scenario many patients face: what to do when weight loss slows down even at a maximum tolerated dose of an injectable GLP-1 drug ^[1].

Why it matters for patients

Many people using Mounjaro, Zepbound, Ozempic, or Wegovy reach a point where their weight loss levels off, even while staying on the highest dose their body can tolerate. This trial speaks directly to that situation by testing whether switching to a daily pill, instead of staying on an injection or increasing dose further, might restart progress or maintain results ^[1].

An oral option like orforglipron could also matter for people who dislike needles, who want a simpler daily routine instead of a weekly injection, or whose insurance coverage or supply access to injectable GLP-1 drugs is inconsistent. But because the specific outcomes of ATTAIN-MAINTAIN are not yet known from the available source, patients cannot yet judge whether switching to an oral GLP-1 medicine actually helped this group lose more weight, maintain their weight loss, or experience different side effects compared with staying on their injectable medicine or taking a placebo ^[1].

It is also not yet known from this source how safety compared between the orforglipron group and the placebo group, which matters because any medicine switch carries some uncertainty about tolerability, especially for people who already needed a maximum dose of a different drug to see results ^[1].

What happens next

The registration record confirms the trial has completed its 52-week treatment period, moving participants from SURMOUNT-5 onto oral orforglipron or placebo ^[1]. Detailed results, including weight-loss figures and safety data, are not included in the source reviewed here and are not yet known. Patients and clinicians watching this trial will likely need a separate results publication or presentation, which has not yet been described in the available record, before drawing conclusions about how well switching to an oral GLP-1 pill worked for people who had plateaued on injectable treatment ^[1].